Mothaffar Rimawi
穆萨法尔·里马维
MD
Medical Director, Lester and Sue Smith Breast Center史密斯乳腺中心医疗主任
👥Biography 个人简介
Mothaffar Rimawi is a leading HER2 biologist and clinician at Baylor, known for elucidating HER2 signaling networks and developing neratinib as an extended adjuvant therapy. His translational research has directly impacted clinical practice in HER2+ breast cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Neratinib in Extended Adjuvant HER2+ Breast Cancer
Led the ExteNET trial establishing neratinib benefit after trastuzumab-based adjuvant therapy, reducing late recurrence in high-risk HER2+ patients.
HER2 Signaling Network Biology
Delineated mechanisms of HER2-driven oncogenesis and resistance to HER2-targeted agents, providing a basis for rational combination therapy design.
Representative Works 代表性著作
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET)
Lancet Oncology (2016)
Demonstrated extended adjuvant neratinib reduced invasive DFS events in high-risk HER2+ patients, supporting FDA approval.
Mechanisms of resistance to HER2-targeted therapies in breast cancer
Cancer Cell (2018)
Characterized adaptive resistance mechanisms in HER2+ breast cancer, identifying rational targets for overcoming therapeutic failure.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 穆萨法尔·里马维 的研究动态
Follow Mothaffar Rimawi's research updates
留下邮箱，当我们发布与 Mothaffar Rimawi（Baylor College of Medicine / Lester and Sue Smith Breast Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment